Skip to main content
. Author manuscript; available in PMC: 2013 May 30.
Published in final edited form as: Am J Transplant. 2011 Nov 9;12(2):313–321. doi: 10.1111/j.1600-6143.2011.03836.x

Figure 5. Comparison of the effects of intact and F(ab’)2DSA on CAV.

Figure 5

(A) A coronary artery from anti-H-2Kk (HB13) mAb treated B6RAG1−/− recipient of a B10.BR heart at day 21 shows marked intimal thickening. (B) Addition of anti-NK1.1 mAb to anti-H-2KkIgG2a mAb eliminated the coronary lesions. (C) Administration of F(ab’)2 fragments of anti-H-2Kk HB13 mAb even in doses 2× that of the intact mAb failed to induce CAV. (D) Control isograft B6RAG1−/− hearts in B6.RAG1−/− recipients given anti-H-2KkIgG2a mAb showed no evidence of vascular lesions. Black arrows indicate coronary arteries.